<DOC>
	<DOCNO>NCT02596893</DOCNO>
	<brief_summary>The purpose study test effect experimental medication GED-0301 ( mongersen ) patient active Crohn 's disease . The study test GED-0301 compare placebo 52 week . The study treatment blind mean patient study doctor know treatment assign . Patients study allow treatment stable dose oral aminosalicylates , oral corticosteroid , immunosupressants antibiotics treatment Crohn 's disease . After 12 week study end study , patient improvement Crohns disease symptom option enter long term active treatment study .</brief_summary>
	<brief_title>Efficacy Safety Study Mongersen ( GED-0301 ) Treatment Subjects With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : Male female â‰¥ 18 year Active Crohn 's disease ( CD ) disease determine Crohn 's Disease Activity Index ( CDAI ) score Simple Endoscopic Score Crohn 's Disease ( SESCD ) Must meet determine average minimum number daily stool rating abdominal pain 7 day period Subject must fail experienced intolerance least one following : budesonide ; systemic corticosteroid ; immunosuppressant ( eg , azathiopurine , 6mercaptopurine , methotrexate ) ; biologics treatment CD . The presence follow exclude subject enrollment : Diagnosis ulcerative colitis ( UC ) , indeterminate colitis , ischemic colitis , microscopic colitis , radiation colitis diverticular diseaseassociated colitis Local manifestation Crohn 's Disease ( CD ) symptomatic/severe strictures , abscess , short bowel syndrome ; disease complication surgery might indicate could confound evaluation efficacy Intestinal resection within 6 month intraabdominal surgery within 3 month prior Screening Visit Ileostomy colostomy Subject history clinically significant medical condition , investigator 's opinion , would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>GED-0301</keyword>
	<keyword>Mongersen</keyword>
	<keyword>IBD</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>